sera of patients with primary biliary cirrhosis (PBC) has been demonstrated, 5 raising the hypothesis that this antigen may therefore represent an autoantigenic trigger. In the The PML (for 'ProMyelocytic Leukemia') gene product is a nuclear zinc finger protein, identified when the same way, 70% of patients with other autoimmune diseases and antibodies against Sp100 (another nuclear dot antigen) chromosomal translocation fusing this gene to the retinoic acid receptor was found in acute promyelocytic leualso also had circulating anti-PML antibodies.
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5
Chronic graft-versus-host disease (GVHD) is a frequent kemia. Recently, a frequent occurrence of autoantibodies against the PML protein was detected in primary and disabling complication of bone marrow transplantation whose pathogenesis is still not well understood. In contrast biliary cirrhosis (PBC) sera, suggesting that this protein could represent an autoantigenic trigger in PBC.
with acute GVHD where donor anti-host T cells have been shown to be solely involved, 6,7 the pathogenesis of chronic Chronic GVHD features are close to those of PBC and in addition, antinuclear and antinucleolar antibodies GVHD seems to rely on a complex interaction between alloimmune and autoimmune mechanisms. 8, 9 Liver chronic are frequently detected in patients' sera. In order to determine if an abnormal expression of PML, followed GVHD is very close to PBC. In view of this similarity and in order to determine if an abnormal expression of PML by the development of anti-PML antibodies, can be implicated in chronic GVHD pathogenesis, we studied followed by the development of anti-PML antibodies can be implicated in chronic GVHD pathogenesis, we studied the expression of PML in the skin of seven patients with chronic GVHD as well as the presence of circulating the expression of PML in the skin and the presence of circulating anti-PML antibodies. anti-PML antibodies. PML was highly expressed by the lesional skin keratinocytes, but circulating antibodies were never detected. PML is induced by interferon (IFN)␥. The expression of PML by GVHD epidermis is likely secondary to the IFN␥ produced by infiltrating Patients and methods lymphocytes. Since PML display growth suppressor properties, the role of this protein in tissue lesions is disPatients cussed. Keywords: GVHD; PML; skin Seven patients with chronic GVHD included in this study are summarized in Table 1 . All had cutaneous lesions and four also had liver GVHD. Cutaneous biopsies were done The non-random chromosomal translocation t(15; 17) on the lesions and when possible on non-lesional skin also. characteristic of the acute promyelocytic leukemia (APL) Positive controls were obtained from patients with psoriasis has led to the identification of a fusion between the PML (a disease already shown to be associated with PML gene (for 'ProMyelocytic Leukemia') present on chromoexpression in keratinocytes). Negative controls were done some 15 and the retinoic acid receptor (RAR␣) on chromoon normal skin specimens obtained from breast plastic sursome 17.
1 The PML gene product is a 90 kDa nuclear gery and two patients with adverse drug reaction. matrix phosphorylated protein 2 which belongs to a new The sera were drawn at the same time as biopsies, before family of C 3 HC 4 zinc finger proteins including the recombiimmunosuppressive treatment was instituted or modified. nase activating RAG-1 gene and the major histocompatibility complex RING-1 gene.
3 PML does not seem to be rigidly attached to the nuclear bodies, but rather shuttles Immunohistochemistry within the nucleus. 4 However, its precise role is still unknown. In vivo, PML is not found in rapidly cycling epiImmunohistochemical studies were performed on cryostatthelia, like skin and colon, but its expression has been cut sections (4-6 m) by an indirect biotin-antibody conjushown in diseases such as psoriasis, skin squamous carcigation technique. Lesional and non-lesional sections were noma and non-invasive breast cancer. 4 Furthermore, the freanalyzed. Sections were fixed in cold acetone and incubated quent presence of circulating antibodies against PML in the with normal mouse serum for 30 min at room temperature. Afterwards, polyclonal rabbit anti-PML (1/100) was added for 30 min. The sections were washed with PBS, then incu- cGVHD = chronic graft-versus-host disease; CML = chronic myeloid leukemia; AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia; TBI = total body irradiation; CY = cyclophosphamide; Eto = etoposide; Mel = melphalan; CytA = cytarabine; CCNU = carmustine.
Detection of circulating anti-PML antibodies
Most cell line cultures express high levels of PML. Detection of circulating anti-PML antibodies was therefore done on Hela cells spotted on superfrost slides. The patients' sera were incubated at different dilutions (1/1, 1/100, 1/250, 1/500). The evaluation was done with fluoresceinated antihuman immunoglobulins.
Results

PML is expressed by keratinocytes of chronic GVHD lesions
Immunohistochemistry with the anti-PML antibodies disclosed a typical nuclear speckled pattern on skin lesional sections of six out seven patients with chronic GVHD (Figures 1 and 2) . The positive cells were basal and suprabasal keratinocytes. In these samples, PML was clearly associated with nuclear bodies. Conversely, no expression of PML in the non-lesional skin of the same patients was ever seen in any of the five specimens analyzed (Figure 3 ). Controls from breast surgery or adverse drug reaction specimens were not labelled while as expected, psoriatic skin was labelled.
Patient's sera do not display anti-PML antibodies
By indirect immunofluorescence, the presence of circulating anti-PML antibodies was never detected in the chronic GVHD patients' sera. The aim of this work was to determine if, similarly to what has been shown in PBC, autoreactivity against PML was expression was never found in non-lesional skin, or in normal skin and was therefore restricted to chronic GVHD present in chronic GVHD. We therefore analyzed PML circulating antibodies and expression of this protein in dissites. As previously stated, PML is a nuclear protein, but its role remains to be determined. 3 Recent analysis of the eased tissues, using a rabbit polyclonal antibody which has been previously shown to be highly specific for this proupstream 5′ genomic sequence of PML gene has shown the presence of an interferon ␣/␤-stimulated response element tein. 10 We found intense expression of PML in the nuclei of keratinocytes in the lesional skin of chronic GVHD. This and an IFN␥ activation site. 11 PML can therefore be con-
The addition of antibodies to TNF␣ and IFN␥ to these supernatants inhibit their ability to induce GVHD. 13 Peripheral blood lymphocytes of chronic GVHD patients express IFN␥ mRNA 14 and recently, IFN␥ mRNA was demonstrated in skin biopsies of chronic GVHD by RT-PCR. 15 We also found IFN␥ mRNA by RT-PCR (personal communication) in other patients' cutaneous chronic GVHD specimens. Therefore, the strong expression of PML is likely secondary to IFN␥ secreted by the GVHD lymphoid infiltrate. This hypothesis fits well with the expression of PML in psoriasis 3 since in this disease, Th1 cells producing IFN␥ have been recently demonstrated. 16 Despite the expression of PML in the skin lesions of chronic GVHD, our patients do not display anti-PML antibodies in contrast with what is found in PBC and other auto-immune diseases.
5 This absence is rather curious since features of chronic GVHD are close to those of PBC (including the presence of antimitochondrial antibodies) 17 and since antinuclear 18 and antinucleolar 19 antibodies are frequently detected in chronic GVHD sera. A peculiar picture is therefore found in chronic GVHD characterized by strong expression of PML in lesional skin without the development of autoantibodies.
Recent studies from our laboratory using the in situ nick end labelling method have demonstrated the presence of numerous apoptotic keratinocytes in skin chronic GVHD lesions. 20 The overexpression of PML in these same cells fits well with this finding. Indeed, PML transfection experiments have demonstrated that this protein is able to suppress the transformation of rat embryo fibroblasts by cooperating oncogenes.
21 PML is therefore considered to be a growth suppressor gene and some authors believe that PML may mediate part of the antiproliferative activity of inter- ferons. 4 In conclusion, chronic GVHD lesions are characterized by an overexpression of PML by keratinocytes, which may be the consequence of the secretion of IFN␥ by the T cell infiltrate, and a growth arrest coincident with apoptosis. These molecular features may participate in the pathogenesis of this disease. sidered as a primary target gene for interferons. 11 The role 347: 558-561.
of IFN␥ in the development of acute and chronic GVHD 
